Efficacy and Safety of the Arsenic Trioxide/Lipiodol Emulsion in the Transcatheter Arterial Chemoembolization Combined with Apatinib in the Treatment of Advanced Hepatocellular Carcinoma

Figure 4

(a) Comparison of PFS between patients with tumor burden ≤50% and tumor burden >50% after the combination of aTACE and apatinib therapy. The median PFS was 7.400 months (95% CI: 6.704–8.096) for patients with tumor burden >50% versus 13.200 months (95% CI: 11.000–15.400) for tumor burden ≤50% (, log-rank test). (b) Comparison of OS between patients with tumor burden ≤50% and tumor burden >50% after the combination of aTACE and apatinib therapy. The median OS was 13.700 months (95% CI: 11.355–16.045) for patients with tumor burden >50% versus 29.600 months (95% CI: 26.881–32.319) with tumor burden ≤50% (, log-rank test). The 1-, 2-, and 3-year OS rates in patients with tumor burden >50% were 62.7%, 12.5%, and 0.0%, respectively, and the 1-, 2-, and 3-year OS rates in patients with tumor burden ≤50% were 96.1%, 70.0%, and 12.3%, respectively. PFS, progression-free survival; OS, overall survival; aTACE, arsenic trioxide transcatheter arterial chemoembolization.

(a)

(b)